Chemokine receptors in vascular biology: a review of current evidence, implications, and therapeutic targets for hypertension.

IF 7.7 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Luis Henrique Oliveira de Moraes, Tyler Beling, Gustavo Felix Pimenta, Thiago Bruder-Nascimento
{"title":"Chemokine receptors in vascular biology: a review of current evidence, implications, and therapeutic targets for hypertension.","authors":"Luis Henrique Oliveira de Moraes, Tyler Beling, Gustavo Felix Pimenta, Thiago Bruder-Nascimento","doi":"10.1042/CS20257214","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, including in the United States. Risk factors such as high cholesterol, diabetes, obesity, smoking, physical inactivity, and hypertension contribute significantly to their development. Emerging evidence highlights a central role for chemokines-small signaling molecules that guide immune cell migration to sites of infection, inflammation, or tissue damage-in the initiation and progression of hypertension. This positions chemokines and their receptors as promising pharmacological targets for blood pressure regulation and vascular protection. In this review, we explore the therapeutic potential of targeting chemokines and their receptors and summarize the main strategies reported in the literature for managing hypertension through these pathways. For this purpose, an analysis of drugs that act on the most relevant receptors at the preclinical and clinical levels was performed. After this analysis, their mechanisms of action, selectivity, and possible adverse effects were discussed. In conclusion, we reinforce that the modulation of chemokines and their receptors represents a promising approach in the control of CVDs, especially hypertension, although further clinical studies are needed to validate the efficacy and safety of this strategy, considering possible impacts on other essential immune responses.</p>","PeriodicalId":10475,"journal":{"name":"Clinical science","volume":"139 16","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12493178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1042/CS20257214","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, including in the United States. Risk factors such as high cholesterol, diabetes, obesity, smoking, physical inactivity, and hypertension contribute significantly to their development. Emerging evidence highlights a central role for chemokines-small signaling molecules that guide immune cell migration to sites of infection, inflammation, or tissue damage-in the initiation and progression of hypertension. This positions chemokines and their receptors as promising pharmacological targets for blood pressure regulation and vascular protection. In this review, we explore the therapeutic potential of targeting chemokines and their receptors and summarize the main strategies reported in the literature for managing hypertension through these pathways. For this purpose, an analysis of drugs that act on the most relevant receptors at the preclinical and clinical levels was performed. After this analysis, their mechanisms of action, selectivity, and possible adverse effects were discussed. In conclusion, we reinforce that the modulation of chemokines and their receptors represents a promising approach in the control of CVDs, especially hypertension, although further clinical studies are needed to validate the efficacy and safety of this strategy, considering possible impacts on other essential immune responses.

血管生物学中的趋化因子受体:当前高血压的证据、意义和治疗靶点综述。
心血管疾病(cvd)仍然是世界范围内死亡的主要原因,包括在美国。高胆固醇、糖尿病、肥胖、吸烟、缺乏运动和高血压等危险因素对其发展有重要影响。新出现的证据强调了趋化因子(引导免疫细胞迁移到感染、炎症或组织损伤部位的小信号分子)在高血压的发生和发展中的核心作用。这使得趋化因子及其受体成为血压调节和血管保护的有希望的药理学靶点。在这篇综述中,我们探讨了靶向趋化因子及其受体的治疗潜力,并总结了文献中报道的通过这些途径治疗高血压的主要策略。为此,在临床前和临床水平上对作用于最相关受体的药物进行了分析。在此基础上,讨论了它们的作用机理、选择性和可能的不良反应。总之,我们强调,趋化因子及其受体的调节是控制心血管疾病,特别是高血压的一种有希望的方法,尽管考虑到可能对其他基本免疫反应的影响,需要进一步的临床研究来验证该策略的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical science
Clinical science 医学-医学:研究与实验
CiteScore
11.40
自引率
0.00%
发文量
189
审稿时长
4-8 weeks
期刊介绍: Translating molecular bioscience and experimental research into medical insights, Clinical Science offers multi-disciplinary coverage and clinical perspectives to advance human health. Its international Editorial Board is charged with selecting peer-reviewed original papers of the highest scientific merit covering the broad spectrum of biomedical specialities including, although not exclusively: Cardiovascular system Cerebrovascular system Gastrointestinal tract and liver Genomic medicine Infection and immunity Inflammation Oncology Metabolism Endocrinology and nutrition Nephrology Circulation Respiratory system Vascular biology Molecular pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信